AXL and acute myeloid leukemia: The BERGAMO multicenter phase 2 trial (NCT03824080) evaluated the safety and efficacy of the oral, selective, small molecule AXL inhibitor bemcentinib (BEM) in patients with HR-MDS or AML not eligible for IC or alloSCT, refractory or relapsing after at least six cycles of azacitidine (AZA) or four cycles of decitabine (DAC).